R-CODOX-M Alternating with R-IVAC Regimen

**Semantic type:** Therapeutic or Preventive Procedure

**Definition:** A regimen consisting of rituximab, cyclophosphamide, vincristine, doxorubicin and high-dose methotrexate (R-CODOX-M) alternating with rituximab, ifosfamide, etoposide and high-dose cytarabine (R-IVAC) that may be used in the treatment of non-Hodgkin lymphoma (NHL), including Burkitt lymphoma.

**Synonyms:** - R-CODOX-M Alternating With R-IVAC - R-CODOX-M/R-IVAC - R-CODOX-M/R-IVAC - R-CODOX-M/R-IVAC (rituximab-abbs) - R-CODOX-M/R-IVAC (rituximab-arrx) - R-CODOX-M/R-IVAC (rituximab-blit) - R-CODOX-M/R-IVAC (rituximab-pvvr) - R-CODOX-M/R-IVAC (rituximab-rite) - R-CODOX-M/R-IVAC (rituximab-rixa) - R-CODOX-M/R-IVAC (rituximab-rixi) - R-CODOX-M/R-IVAC Regimen - R-IVAC + R-CODOX-M - R-IVAC Alternating with R-CODOX-M - Rituximab/Cyclophosphamide/Oncovin/Doxorubicin/Methotrexate and Rituximab/Ifosfamide/VePesid/AraC Regimen - Rituximab/Cyclophosphamide/Vincristine/Doxorubicin/Methotrexate and Rituximab/Ifosfamide/Etoposide/Cytarabine